Analytical Data
-
Gene name
Coagulation factor IX/F9
- Application
-
Alternative Names
(Christmas factor)(Plasma thromboplastin component)(PTC)
-
Species
Human
-
Source
E. coli
-
Tag
N- His-GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P00740
-
Expression Region
144-239aa
-
Molecular Weight
42.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Coagulation factor IX (F9) is a crucial protein in the blood coagulation cascade, primarily responsible for the activation of factor X, which ultimately leads to thrombin formation and fibrin clot development. Deficiency or dysfunction of factor IX results in Hemophilia B, a genetic bleeding disorder that affects predominantly males and leads to spontaneous or prolonged bleeding episodes. Advances in the understanding of the molecular mechanisms underlying Hemophilia B have paved the way for the development of recombinant factor IX products, which provide a therapeutic option for patients. These recombinant proteins are synthesized using recombinant DNA technology, allowing for the production of highly purified and safe products that can replace the deficient coagulation factor in affected individuals. Research has focused on improving the pharmacokinetic properties of these proteins to enhance their efficacy and reduce the frequency of administration. Additionally, studies are investigating the use of gene therapy as a potential long-term solution for Hemophilia B, offering the promise of sustained factor IX production within patients. The ongoing innovations in recombinant factor IX therapeutics reflect the need for more effective and accessible treatments for individuals living with this condition, ultimately aiming to improve their quality of life and outcomes in clinical settings.
